NULOJIX 250 MG
Country: Israel
Language: English
Source: Ministry of Health
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
BELATACEPT 25 MG/ML
Available from:
BRISTOL-MYERS SQUIBB (ISRAEL) LIMITED
ATC code:
L04AA28
Pharmaceutical form:
POWDER FOR CONCENTRATE FOR INFUSION
Administration route:
I.V
Manufactured by:
BRISTOL-MYERS SQUIBB S.R.L, ITALY
Therapeutic group:
BELATACEPT
Therapeutic indications:
Nulojix, in combination with corticosteroids and mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen
Authorization date:
2012-08-01
